Invion Limited
OTC: IVIXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thian Chew
- Employees
- 4
- Headquarters
- Melbourne, Australia
- IPO year
- 2013
- Market cap
- $4.0M
- Website
- https://www.inviongroup.com
Loading IVIXF…
Loading profile data…Frequently asked questions about IVIXF
What does Invion Limited (IVIXF) do?
Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as thos...
Where does IVIXF trade?
Invion Limited (IVIXF) trades on the Other OTC.
What sector is IVIXF in?
Invion Limited (IVIXF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Invion Limited?
Thian Chew is the chief executive officer of Invion Limited (IVIXF).
Where is Invion Limited headquartered?
Invion Limited is headquartered in Australia.
Does IVIXF pay a dividend?
Invion Limited (IVIXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IVIXF go public?
Invion Limited (IVIXF) completed its initial public offering in 2013.